PTC Therapeutics (FRA:BH3) Marketable Securities: €1,023.5 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BH3 PTC Therapeutics Inc FRA:BH3
53 GF Score
Price €65.44
GF Value €35.22
! 7 Warning Signs
View Full Analysis

What is PTC Therapeutics Marketable Securities?

PTC Therapeutics FRA:BH3 +1.65% 53 Marketable Securities is €1,023.5 Mil as of Jun. 2026. GuruFocus rates FRA:BH3 with a GF Score™ of 53/100 and a GF Value™ of €35.22. The stock has 7 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. PTC Therapeutics's Marketable Securities for the quarter that ended in Jun. 2026 was €1,023.5 Mil.

PTC Therapeutics's annual Marketable Securities increased from Dec. 2023 (€259.3 Mil) to Dec. 2024 (€343.8 Mil) and increased from Dec. 2024 (€343.8 Mil) to Dec. 2025 (€820.5 Mil).

PTC Therapeutics  (FRA:BH3) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

PTC Therapeutics Marketable Securities Related Terms

PTC Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for PTC Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PTC Therapeutics Marketable Securities Chart

PTC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 516.54 123.54 259.27 343.79 820.46

PTC Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 842.52 864.95 820.46 915.58 1,023.54
FRA:BH3
53GF Score
PTC Therapeutics Inc FRA:BH3
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PTC Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of €1,023.5 Mil mean?
PTC Therapeutics (FRA:BH3) has a Marketable Securities of €1,023.5 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on PTC Therapeutics and its competitors.
Is PTC Therapeutics' Marketable Securities too high?
PTC Therapeutics' current Marketable Securities is €1,023.5 Mil. Overall, PTC Therapeutics has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' Marketable Securities compare to XENE and CGON?
PTC Therapeutics' Marketable Securities of €1,023.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on PTC Therapeutics and its competitors. PTC Therapeutics's current Marketable Securities is €1,023.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
PTC Therapeutics (FRA:BH3) has a current Marketable Securities of €1,023.5 Mil. The stock's GF Value™ is €35.22, compared to a current price of €65.44 — trading 85.8% above its estimated fair value. The current Marketable Securities is €1,023.5 Mil. PTC Therapeutics' overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For PTC Therapeutics (FRA:BH3), the current Marketable Securities is €1,023.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of €65.44 is trading 85.8% above its estimated GF Value™ of €35.22.

Key valuation signals for FRA:BH3:

  • Marketable Securities: €1,023.5 Mil
  • GF Value™: €35.22 vs. price of €65.44 (85.8% above fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PTC Therapeutics Business Description

Other Exchanges PTCT:USABH3:Germany
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
53GF Score

Get the complete analysis for FRA:BH3

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.44
Price
€35.22
GF Value